Conference Coverage

Wrap-Up: Diabetes and Liver Disease

Wendy Wright, DNP, ANP-BC, FNP-BC

In this video, Wendy Wright, DNP, ANP-BC, FNP-BC, provides an overview of the session "Diabetes and Liver Disease: Exploring the Intersections and Best Practices," at our Practical Updates in Primary Care 2023 Virtual Series, including a case study of a patient with non-alcoholic fatty liver disease, an overview of tools that are available to help make the diagnosis, and identify patients who are at risk of progression to cirrhosis or hepatocellular carcinoma, and more.  

For more meeting coverage, visit the Practical Updates in Primary Care newsroom.

For more information about PUPC 2023 Virtual Series and to register for upcoming sessions, visit

Wendy Wright, DNP, ANP-BC, FNP-BC

Wendy Wright, DNP, ANP-BC, FNP-BC, is is an adult & family nurse practitioner and owner of Wright & Associates Family Healthcare (Amherst, NH). 



Dr Wendy Wright: Well, thank you so much for joining us for our session on diabetes and liver disease, exploring the intersections and best practices. I am Dr Wendy Wright, an adult and family nurse practitioner and the owner of a nurse practitioner-owned and operated primary care clinic located in New Hampshire.

I was joined by Dr Peter Buch and by Dr Carol Wysham, and throughout the course of this lecture, we used a case study to help walk you through a patient with non-alcoholic fatty liver, helped you to identify those tools that are available to make the diagnosis, as well as identify those patients who are at risk for progressing on or who have already progressed on to cirrhosis and potentially hepatocellular carcinoma.

Throughout the course of this lecture, we not only discussed tools for diagnosis, but we also gave you a number of interventions that you can use with your patients, everything from lifestyle modifications, such as diet and exercise, eliminating sugar beverages, such as soda. We even talked about the best diets. We also discussed a number of different pharmaceutical agents that are available that can change the trajectory of non-alcoholic fatty liver and fatty liver disease.

So thank you so much. It was our pleasure to be on the stage, and we hope you thoroughly enjoyed this lecture.